مباشر

FierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2 Endpoints NewsHikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug CellPaleogenomes reveal the evolutionary relationship between modern and cave lions Endpoints NewsLilly, Boehringer retrench in Germany on proposed health spending cuts Endpoints NewsSupreme Court sides with Hikma in 'skinny label' case FierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Endpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinic BioPharma DiveAlnylam, Inceptive ink AI deal potentially worth $2B FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3 Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract Pharma Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times

FierceBiotech ٢٧ فبراير ٢٠٢٦

Chutes & Ladders—Sarepta CEO to step down as DM1 hits close to home

Chutes & Ladders—Sarepta CEO to step down as DM1 hits close to home

المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.